Lake Street Capital Forecasts Strong Price Appreciation for LeMaitre Vascular (NASDAQ:LMAT) Stock

LeMaitre Vascular (NASDAQ:LMAT) had its price objective upped by Lake Street Capital from $105.00 to $110.00 in a research note released on Friday,Benzinga reports. The firm currently has a buy rating on the medical instruments supplier’s stock.

Other research analysts have also issued reports about the company. Wells Fargo & Company initiated coverage on LeMaitre Vascular in a report on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 price objective on the stock. Barrington Research lowered LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday. Oppenheimer lowered LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday. Finally, StockNews.com lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Five investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $95.25.

LeMaitre Vascular Trading Down 8.1 %

LMAT opened at $91.85 on Friday. LeMaitre Vascular has a 1-year low of $62.39 and a 1-year high of $109.58. The stock’s fifty day simple moving average is $96.90 and its 200 day simple moving average is $94.66. The stock has a market cap of $2.07 billion, a PE ratio of 50.19, a price-to-earnings-growth ratio of 2.22 and a beta of 0.96.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.49. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business had revenue of $55.81 million for the quarter, compared to analysts’ expectations of $55.99 million. Equities analysts forecast that LeMaitre Vascular will post 1.94 earnings per share for the current year.

Institutional Trading of LeMaitre Vascular

Several large investors have recently bought and sold shares of LMAT. Raymond James Financial Inc. bought a new position in LeMaitre Vascular in the fourth quarter valued at about $14,900,000. Rockefeller Capital Management L.P. bought a new position in LeMaitre Vascular in the fourth quarter valued at about $7,787,000. Segall Bryant & Hamill LLC bought a new position in LeMaitre Vascular in the fourth quarter valued at about $5,446,000. Invesco Ltd. raised its position in LeMaitre Vascular by 50.5% in the fourth quarter. Invesco Ltd. now owns 174,998 shares of the medical instruments supplier’s stock valued at $16,124,000 after purchasing an additional 58,720 shares during the last quarter. Finally, DF Dent & Co. Inc. raised its position in LeMaitre Vascular by 26.2% in the third quarter. DF Dent & Co. Inc. now owns 258,767 shares of the medical instruments supplier’s stock valued at $24,037,000 after purchasing an additional 53,797 shares during the last quarter. 84.64% of the stock is owned by institutional investors and hedge funds.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.